Related Experiment Video
Updated: Jun 12, 2025
Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography
Published on: November 1, 2024
Retrospective cohort study of Helicobacter pylori infection and risk stratification using 6-year UBT data
Yan Chen1, Miaojuan Wang1, Jianfeng Wang2,3
1Department of General Practice, The First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Provincial Hospital of Traditional Chinese Medicine, Hangzhou, China.
Background:
Helicobacter pylori (H. pylori) infection is a major global health concern, linked to gastric cancer and metabolic disorders. Despite its widespread prevalence, accurate risk stratification remains challenging. This study aims to develop a machine learning (ML)-based risk prediction model using 6-year longitudinal Urea Breath Test (UBT) data to identify metabolic alterations associated with chronic H. pylori infection.
Methods:
A retrospective cohort study was conducted using health examination data from 3,409 individuals between 2016 and 2021. Participants were stratified into H. pylori-positive and negative groups based on longitudinal UBT results. Key metabolic markers, including HbA1c, LDL-C, BMI, and WBC, were analyzed. Three predictive models-logistic regression, random forest, and XGBoost-were compared to assess their predictive performance.
Results:
Among the cohort, 20.5% exhibited chronic H. pylori infection. Infected individuals had significantly higher HbA1c (+1.2%, p < 0.01), LDL-C (+15 mg/dL, p < 0.05), and WBC levels, alongside lower albumin (-0.8 g/dL, p < 0.01). The XGBoost model outperformed others (AUC = 0.6809, Accuracy = 81.13%) in predicting infection risk. A subgroup of 4.0% was identified as high-risk, highlighting the potential for early intervention.
Conclusion:
This study underscores the interplay between chronic H. pylori infection and metabolic dysfunction, offering new perspectives on risk prediction using machine learning. The XGBoost model demonstrated reliable performance in stratifying infection risk based on accessible clinical markers. Its integration into routine screening protocols could enhance early detection and personalized intervention strategies. Further studies should validate these findings across broader populations and incorporate additional risk factors.
Related Concept Videos
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
01:30Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
01:28Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.